Skip to main content
Erschienen in: Clinical and Translational Oncology 6/2015

01.06.2015 | Research Article

Effects of zoledronate on the radiation-induced collagen breakdown: a prospective randomized clinical trial

verfasst von: M. Gierloff, M. Reutemann, A. Gülses, P. Niehoff, J. Wiltfang, Y. Açil

Erschienen in: Clinical and Translational Oncology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

A negative side effect of therapeutic irradiation is the radiation-induced bone loss which can lead, in long term, to pathological fractures. Until today, the detailed mechanism is unknown. If osteoclasts would mainly contribute to the pathological bone loss, bisphosphonates could potentially counteract the osteolytic process and possibly help to prevent long-term complications. The aim of this study was to evaluate the effect of zoledronic acid on the early radiation-induced degradation of bone collagen fibrils by monitoring the urinary excretion of hydroxylysylpyridinoline and lysylpyridinoline under radiotherapy.

Patients and methods

A total of 40 patients with skeletal metastases were assigned for a local radiotherapy and bisphosphonate treatment. The patients were prospectively randomized into two treatment groups: group A (n = 20) received the first zoledronate administration after and group B (n = 20) prior to the radiotherapy. Urine samples were collected from each patient on the first day, in the middle, and on the last day of the radiation therapy. Measurement of the bone metabolites hydroxylysylpyridinoline and lysylpyridinoline was performed by high-performance liquid chromatography. Statistical analysis was performed using the Mann–Whitney U test.

Results

The hydroxylysylpyridinoline and lysylpyridinoline excretion decreased significantly in the combined bisphosphonate and radiotherapy group (p = 0.02, p = 0.08). No significant change of the hydroxylysylpyridinoline and lysylpyridinoline excretion was determined in the patients that received solely irradiation.

Conclusion

The results indicate the ability of zoledronate to prevent the early radiation-induced bone collagen degradation suggesting that the radiation-induced bone loss is mainly caused by osteoclastic bone resorption rather than by a direct radiation-induced damage.
Literatur
1.
Zurück zum Zitat Freundt K, Meyners T, Bajrovic A, Basic H, Karstens JH, Adamietz IA, et al. Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors. Strahlenther Onkol. 2010;186:218–23.CrossRefPubMed Freundt K, Meyners T, Bajrovic A, Basic H, Karstens JH, Adamietz IA, et al. Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors. Strahlenther Onkol. 2010;186:218–23.CrossRefPubMed
2.
Zurück zum Zitat Sauer N, Leising D, Wild B, Treiber M, Henningsen P, Jakobsen T. Pain and quality of life following palliative radiotherapy of bone metastases. Strahlenther Onkol. 2006;182:550–6.CrossRefPubMed Sauer N, Leising D, Wild B, Treiber M, Henningsen P, Jakobsen T. Pain and quality of life following palliative radiotherapy of bone metastases. Strahlenther Onkol. 2006;182:550–6.CrossRefPubMed
3.
Zurück zum Zitat van Oorschot B, Schuler M, Simon A, Schleicher U, Geinitz H. Patterns of care and course of symptoms in palliative radiotherapy: a multicenter pilot study analysis. Strahlenther Onkol. 2011;187:461–6.CrossRefPubMed van Oorschot B, Schuler M, Simon A, Schleicher U, Geinitz H. Patterns of care and course of symptoms in palliative radiotherapy: a multicenter pilot study analysis. Strahlenther Onkol. 2011;187:461–6.CrossRefPubMed
4.
Zurück zum Zitat Mose S, Pfitzner D, Rahn A, Nierhoff C, Schiemann M, Bottcher HD. Role of radiotherapy in the treatment of multiple myeloma. Strahlenther Onkol. 2000;176:506–12.CrossRefPubMed Mose S, Pfitzner D, Rahn A, Nierhoff C, Schiemann M, Bottcher HD. Role of radiotherapy in the treatment of multiple myeloma. Strahlenther Onkol. 2000;176:506–12.CrossRefPubMed
5.
Zurück zum Zitat Ogino I, Okamato N, Ono Y, Kitamura T, Nakayama H. Pelvic insuffiency fractures in postmenopausal woman with advanced cervical cancer treated by radiotherapy. Radiother Oncol. 2003;68:61–7.CrossRefPubMed Ogino I, Okamato N, Ono Y, Kitamura T, Nakayama H. Pelvic insuffiency fractures in postmenopausal woman with advanced cervical cancer treated by radiotherapy. Radiother Oncol. 2003;68:61–7.CrossRefPubMed
6.
Zurück zum Zitat Schmeler KM, Jhingran A, Iyer RB, Sun CC, Eifel PJ, Soliman PT, et al. Pelvic fractures after radiotherapy for cervical cancer: implications for survivors. Cancer. 2010;116:625–30.CrossRefPubMed Schmeler KM, Jhingran A, Iyer RB, Sun CC, Eifel PJ, Soliman PT, et al. Pelvic fractures after radiotherapy for cervical cancer: implications for survivors. Cancer. 2010;116:625–30.CrossRefPubMed
7.
Zurück zum Zitat Stanic S, Bolke TP, Rule WG, Timmermann RD. Rib fracture following stereotactic body radiotherapy: a potential pitfall. Clin Nucl Med. 2011;36:168–70.CrossRef Stanic S, Bolke TP, Rule WG, Timmermann RD. Rib fracture following stereotactic body radiotherapy: a potential pitfall. Clin Nucl Med. 2011;36:168–70.CrossRef
8.
Zurück zum Zitat Dudziak ME, Saadeh PB, Mehrara BJ, Steinbrech DS, Greenwald JA, Gittes GK, et al. The effects of ionizing radiation on osteoblast-like cells in vitro. Plast Reconstr Surg. 2000;106:1049–61.CrossRefPubMed Dudziak ME, Saadeh PB, Mehrara BJ, Steinbrech DS, Greenwald JA, Gittes GK, et al. The effects of ionizing radiation on osteoblast-like cells in vitro. Plast Reconstr Surg. 2000;106:1049–61.CrossRefPubMed
9.
Zurück zum Zitat Ural AU, Avcu F, Baran Y. Bisphosphonate treatment and radiotherapy in metastatic breast cancer. Med Oncol. 2008;25:350–5.CrossRefPubMed Ural AU, Avcu F, Baran Y. Bisphosphonate treatment and radiotherapy in metastatic breast cancer. Med Oncol. 2008;25:350–5.CrossRefPubMed
10.
Zurück zum Zitat Szymcyk KH, Shapiro IM, Adams CS. Ionizing radiation sensitizes bone cells to apoptosis. Bone. 2004;34:148–56.CrossRef Szymcyk KH, Shapiro IM, Adams CS. Ionizing radiation sensitizes bone cells to apoptosis. Bone. 2004;34:148–56.CrossRef
11.
Zurück zum Zitat Willey JS, Lloyd SA, Robbins ME, Bourland JD, Smith-Sielicki H, Bowman LC, et al. Early increase in osteoclast number in mice after whole-body irradiation with 2 Gy X rays. Radiat Res. 2008;170:388–92.CrossRefPubMedCentralPubMed Willey JS, Lloyd SA, Robbins ME, Bourland JD, Smith-Sielicki H, Bowman LC, et al. Early increase in osteoclast number in mice after whole-body irradiation with 2 Gy X rays. Radiat Res. 2008;170:388–92.CrossRefPubMedCentralPubMed
12.
Zurück zum Zitat Williams HJ, Davies AM. The effect of X-rays on bone: a pictorial review. Eur Radiol. 2006;16:619–33.CrossRefPubMed Williams HJ, Davies AM. The effect of X-rays on bone: a pictorial review. Eur Radiol. 2006;16:619–33.CrossRefPubMed
13.
Zurück zum Zitat Jereczek-Fossa BA, Orecchia R. Radiotherapy-induced mandibular bone complications. Cancer Treat Rev. 2002;28:65–74.CrossRefPubMed Jereczek-Fossa BA, Orecchia R. Radiotherapy-induced mandibular bone complications. Cancer Treat Rev. 2002;28:65–74.CrossRefPubMed
14.
Zurück zum Zitat Açil Y, Springer IN, Niehoff P, Gassling V, Warnke PH, Açmaz S, et al. Proof of direct radiogenic destruction of collagen in vitro. Strahlenther Onkol. 2007;183:374–9.CrossRefPubMed Açil Y, Springer IN, Niehoff P, Gassling V, Warnke PH, Açmaz S, et al. Proof of direct radiogenic destruction of collagen in vitro. Strahlenther Onkol. 2007;183:374–9.CrossRefPubMed
15.
Zurück zum Zitat Inoue Y, Miki C, Ojima E, Nomoto J, Kusunoki M. Pelvic insufficiency factures after preoperative radiotherapy for rectal carcinoma. Int J Clin Oncol. 2003;8:336–9.CrossRefPubMed Inoue Y, Miki C, Ojima E, Nomoto J, Kusunoki M. Pelvic insufficiency factures after preoperative radiotherapy for rectal carcinoma. Int J Clin Oncol. 2003;8:336–9.CrossRefPubMed
16.
Zurück zum Zitat Niehoff P, Wiltfang J, Springer IN, Weppner N, Kimmig B, Açil Y. Increased excretion of collagen crosslinks in irradiated patients indicates destruction of collagen. Int J Radiat Biol. 2006;82:503–9.CrossRefPubMed Niehoff P, Wiltfang J, Springer IN, Weppner N, Kimmig B, Açil Y. Increased excretion of collagen crosslinks in irradiated patients indicates destruction of collagen. Int J Radiat Biol. 2006;82:503–9.CrossRefPubMed
17.
Zurück zum Zitat Springer ING, Terheyden H, Dunsche A, Czech N, Tiemann M, Hedderich J, et al. Collagen crosslink excretion and staging of oral cancer. Br J Cancer. 2003;88:1105–10.CrossRefPubMedCentralPubMed Springer ING, Terheyden H, Dunsche A, Czech N, Tiemann M, Hedderich J, et al. Collagen crosslink excretion and staging of oral cancer. Br J Cancer. 2003;88:1105–10.CrossRefPubMedCentralPubMed
18.
Zurück zum Zitat Burr DB. The contribution of the organic matrix to bone’s material properties. Bone. 2002;31:8–11.CrossRefPubMed Burr DB. The contribution of the organic matrix to bone’s material properties. Bone. 2002;31:8–11.CrossRefPubMed
19.
Zurück zum Zitat Kini U, Nandeesh BN. Physiology of boneformation, remodelling and metabolism. In: Fogelman I, Gnanasegaran G, van der Wall H, editors. Radionuclideand hybrid bone imaging, vol. XIV. 2012. p. 29–57.CrossRef Kini U, Nandeesh BN. Physiology of boneformation, remodelling and metabolism. In: Fogelman I, Gnanasegaran G, van der Wall H, editors. Radionuclideand hybrid bone imaging, vol. XIV. 2012. p. 29–57.CrossRef
20.
Zurück zum Zitat Rogers MJ, Crockett JC, Coxon FP, Mönkkönen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone. 2011;49:34–41.CrossRefPubMed Rogers MJ, Crockett JC, Coxon FP, Mönkkönen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone. 2011;49:34–41.CrossRefPubMed
21.
Zurück zum Zitat Coleman RE. Metastatic bone disease: clinical features, pathophysiology, and treatment strategies. Cancer Treat Rev. 2001;27:165–76.CrossRefPubMed Coleman RE. Metastatic bone disease: clinical features, pathophysiology, and treatment strategies. Cancer Treat Rev. 2001;27:165–76.CrossRefPubMed
22.
23.
Zurück zum Zitat Goldhahn J, Feron JM, Kanis J, Papaloulos S, Reginster JY, Rizzoli R, et al. Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int. 2012;90:343–53.CrossRefPubMed Goldhahn J, Feron JM, Kanis J, Papaloulos S, Reginster JY, Rizzoli R, et al. Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int. 2012;90:343–53.CrossRefPubMed
24.
Zurück zum Zitat Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescent with osteogenesis imperfecta. J Clin Invest. 2002;110:1293–9.CrossRefPubMedCentralPubMed Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescent with osteogenesis imperfecta. J Clin Invest. 2002;110:1293–9.CrossRefPubMedCentralPubMed
25.
Zurück zum Zitat Hoskin PJ. Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev. 2003;29:321–7.CrossRefPubMed Hoskin PJ. Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev. 2003;29:321–7.CrossRefPubMed
26.
Zurück zum Zitat Willey JS, Livingston EW, Robbings ME, Bourland JD, Tirado-Lee L, Smith-Sielicki H, et al. Risedronate prevents early radiation-induced osteoporosis in mice at multiple skeletal locations. Bone. 2010;46:101–11.CrossRefPubMedCentralPubMed Willey JS, Livingston EW, Robbings ME, Bourland JD, Tirado-Lee L, Smith-Sielicki H, et al. Risedronate prevents early radiation-induced osteoporosis in mice at multiple skeletal locations. Bone. 2010;46:101–11.CrossRefPubMedCentralPubMed
27.
Zurück zum Zitat Açil Y, Gierloff M, Behrens C, Möller B, Gassling V, Niehoff P, et al. Effects of zoledronate on irradiated bone in vivo: analysis of the collagen types I, V and their crosslinks lysylpyridinoline, hydroxylysylpyridinoline and hydroxyproline. Calcif Tissue Int. 2013;92:251–60.CrossRefPubMed Açil Y, Gierloff M, Behrens C, Möller B, Gassling V, Niehoff P, et al. Effects of zoledronate on irradiated bone in vivo: analysis of the collagen types I, V and their crosslinks lysylpyridinoline, hydroxylysylpyridinoline and hydroxyproline. Calcif Tissue Int. 2013;92:251–60.CrossRefPubMed
28.
Zurück zum Zitat Springer ING, Wiltfang J, Dunsche A, Lier GC, Bartsch M, Warnke PH, et al. A new method of monitoring osteomyelitis. Int J Oral Maxillofac Surg. 2007;36:527–32.CrossRefPubMed Springer ING, Wiltfang J, Dunsche A, Lier GC, Bartsch M, Warnke PH, et al. A new method of monitoring osteomyelitis. Int J Oral Maxillofac Surg. 2007;36:527–32.CrossRefPubMed
29.
Zurück zum Zitat Hoskin PJ, Stratford MR, Folkes LK, Regan J, Yarnold JR. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet. 2000;355:1428–9.CrossRefPubMed Hoskin PJ, Stratford MR, Folkes LK, Regan J, Yarnold JR. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet. 2000;355:1428–9.CrossRefPubMed
30.
Zurück zum Zitat Theriault RL, Theriault RL. Biology of bone metastases. Cancer Control. 2012;19:92–101.PubMed Theriault RL, Theriault RL. Biology of bone metastases. Cancer Control. 2012;19:92–101.PubMed
31.
Zurück zum Zitat Arrington SA, Fisher ER, Willick GE, Mann KA, Allen MJ. Anabolic and antiresorptive drugs improve trabecular microarchitecture and reduce fracture risk following radiation therapy. Calcif Tissue Int. 2010;87:263–72.CrossRefPubMed Arrington SA, Fisher ER, Willick GE, Mann KA, Allen MJ. Anabolic and antiresorptive drugs improve trabecular microarchitecture and reduce fracture risk following radiation therapy. Calcif Tissue Int. 2010;87:263–72.CrossRefPubMed
32.
Zurück zum Zitat Hui SK, Fairchild GR, Kidder LS, Sharma M, Bhattacharya M, Jackson S, et al. Skeletal remodeling following clinically relevant radiation-induced bone damage treated with zoledronic acid. Calcif Tissue Int. 2012;90:40–9.CrossRefPubMed Hui SK, Fairchild GR, Kidder LS, Sharma M, Bhattacharya M, Jackson S, et al. Skeletal remodeling following clinically relevant radiation-induced bone damage treated with zoledronic acid. Calcif Tissue Int. 2012;90:40–9.CrossRefPubMed
33.
Zurück zum Zitat Krempien R, Huber PE, Harms W, Treiber M, Wannenmacher M, Krempien B. Combination of early bisphosphonate administration and irradiation leads to improved remineralization and restabilization of osteolytic bone metastases in an animal tumor model. Cancer. 2003;98:1318–24.CrossRefPubMed Krempien R, Huber PE, Harms W, Treiber M, Wannenmacher M, Krempien B. Combination of early bisphosphonate administration and irradiation leads to improved remineralization and restabilization of osteolytic bone metastases in an animal tumor model. Cancer. 2003;98:1318–24.CrossRefPubMed
Metadaten
Titel
Effects of zoledronate on the radiation-induced collagen breakdown: a prospective randomized clinical trial
verfasst von
M. Gierloff
M. Reutemann
A. Gülses
P. Niehoff
J. Wiltfang
Y. Açil
Publikationsdatum
01.06.2015
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 6/2015
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1257-8

Weitere Artikel der Ausgabe 6/2015

Clinical and Translational Oncology 6/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.